PMID- 8328369
OWN - NLM
STAT- MEDLINE
DCOM- 19930809
LR  - 20190622
IS  - 0002-9149 (Print)
IS  - 0002-9149 (Linking)
VI  - 71
IP  - 17
DP  - 1993 Jun 24
TI  - Acceptability of perindopril in mild-to-moderate chronic congestive heart 
      failure. Results of a long-term open study in 320 patients.
PG  - 61E-68E
AB  - The long-term acceptability of perindopril in mild-to-moderate chronic heart 
      failure (CHF) was evaluated in a multicenter open study. A total of 320 patients 
      with a mean age of 62 +/- 1 years and CHF of New York Heart Association (NYHA) 
      class I (2 patients), II (204 patients), or III (114 patients) were included 
      after a 2-week run-in period during which time vasodilators were stopped and 
      diuretic and/or digoxin therapy stabilized. Perindopril treatment was started at 
      2 mg, increasing to 4 mg once daily after 2 weeks if supine systolic blood 
      pressure remained > 100 mm Hg. After this dose titration period, follow-up visits 
      were scheduled at monthly intervals for the first 3 months, then at 3-month 
      intervals with a maximum period of follow-up being 30 months. At the time of 
      analysis, mean duration of treatment was 276 days and 208 patients were treated > 
      or = 6 months. Of the 320 patients, 10 (3.1%) died, 9 (2.8%) were withdrawn for 
      worsening heart failure, and 38 (11.9%) for nonfatal adverse events, including 
      cough (2.8%), dizziness or orthostatic discomfort (1.9%), angina pectoris (1.6%), 
      and cutaneous signs (1.3%). Exercise test duration increased from 516 +/- 14 to 
      659 +/- 19 sec after 6 months of treatment (p < 0.01). At 6 months, 55.6% of 
      patients improved by at least 1 NYHA class. Supine systolic blood pressure 
      decreased slightly from 137 +/- 2 to 132 +/- 1 mm Hg (p < 0.01) and plasma 
      creatinine levels remained stable from 100 +/- 2 to 102 +/- 2 mumol/liter after 6 
      months of treatment.(ABSTRACT TRUNCATED AT 250 WORDS)
FAU - Desche, P
AU  - Desche P
AD  - Institut de Recherches Internationales Servier, Courbevoie, France.
FAU - Antony, I
AU  - Antony I
FAU - Lerebours, G
AU  - Lerebours G
FAU - Violet, I
AU  - Violet I
FAU - Robert, S
AU  - Robert S
FAU - Weber, C
AU  - Weber C
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Multicenter Study
PL  - United States
TA  - Am J Cardiol
JT  - The American journal of cardiology
JID - 0207277
RN  - 0 (Angiotensin-Converting Enzyme Inhibitors)
RN  - 0 (Indoles)
RN  - Y5GMK36KGY (Perindopril)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Angiotensin-Converting Enzyme Inhibitors/adverse 
      effects/pharmacology/*therapeutic use
MH  - Chronic Disease
MH  - Exercise Test/drug effects
MH  - Female
MH  - Heart Failure/*drug therapy
MH  - Humans
MH  - Indoles/adverse effects/pharmacology/*therapeutic use
MH  - Male
MH  - Middle Aged
MH  - Perindopril
MH  - Treatment Outcome
EDAT- 1993/06/24 00:00
MHDA- 1993/06/24 00:01
CRDT- 1993/06/24 00:00
PHST- 1993/06/24 00:00 [pubmed]
PHST- 1993/06/24 00:01 [medline]
PHST- 1993/06/24 00:00 [entrez]
AID - 0002-9149(93)90955-C [pii]
AID - 10.1016/0002-9149(93)90955-c [doi]
PST - ppublish
SO  - Am J Cardiol. 1993 Jun 24;71(17):61E-68E. doi: 10.1016/0002-9149(93)90955-c.